Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceral adiposity.

Mantovani RM, Rios DR, Moura LC, Oliveira JM, Carvalho FF, Cunha SB, Viana Mde F, Lamounier JA, Castro JC, Dusse LM, Simões e Silva AC.

J Pediatr Endocrinol Metab. 2011;24(5-6):361-7.

PMID:
21823537
2.

Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.

Appel SJ, Harrell JS, Davenport ML.

J Am Acad Nurse Pract. 2005 Dec;17(12):535-41.

PMID:
16293162
3.

NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.

Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP.

Obesity (Silver Spring). 2008 Jun;16(6):1394-9. doi: 10.1038/oby.2008.64. Epub 2008 Mar 27.

4.

Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.

Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, Corsi MM, Ambrosi B.

Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):523-30. Epub 2008 Feb 20.

PMID:
18083357
5.
6.

Relation of leptin to insulin resistance syndrome in children.

Steinberger J, Steffen L, Jacobs DR Jr, Moran A, Hong CP, Sinaiko AR.

Obes Res. 2003 Sep;11(9):1124-30.

7.

Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.

de Larrañaga G, Wingeyer SP, Graffigna M, Belli S, Bendezú K, Alvarez S, Levalle O, Fainboim H.

Clin Appl Thromb Hemost. 2008 Jul;14(3):319-24. Epub 2007 Dec 26.

PMID:
18160600
8.

PAI-1 and the metabolic syndrome: links, causes, and consequences.

Alessi MC, Juhan-Vague I.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2200-7. Epub 2006 Aug 24. Review.

PMID:
16931789
9.

Relationship between changes in plasma leptin concentrations and plasminogen activator inhibitor-1 in obese prepubertal children after nine months of treatment.

Valle Jiménez M, Martos R, Morales RM, Valle R, Cañete MD, Urbano MM, Bermudo F, Cañete R.

Ann Nutr Metab. 2013;63(3):216-22. doi: 10.1159/000351597. Epub 2013 Oct 15.

PMID:
24135306
10.

Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome.

Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, Tambascia M, Bouskela E.

Clinics (Sao Paulo). 2006 Oct;61(5):433-40.

11.

Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: the role of plasminogen activator inhibitor-1 and Haemoglobin A1c.

Boronat M, Saavedra P, Varillas VF, Nóvoa FJ.

Nutr Metab Cardiovasc Dis. 2009 May;19(4):271-6. doi: 10.1016/j.numecd.2008.07.007. Epub 2008 Sep 21.

PMID:
18809301
12.

Human visceral adipose tissue and the plasminogen activator inhibitor type 1.

Lindeman JH, Pijl H, Toet K, Eilers PH, van Ramshorst B, Buijs MM, van Bockel JH, Kooistra T.

Int J Obes (Lond). 2007 Nov;31(11):1671-9. Epub 2007 May 1.

PMID:
17471294
13.
14.

Waist circumference is related to low-grade inflammation in youth.

Steene-Johannessen J, Kolle E, Reseland JE, Anderssen SA, Andersen LB.

Int J Pediatr Obes. 2010 Aug;5(4):313-9. doi: 10.3109/17477160903497035.

PMID:
20078378
15.

Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk?

Alokail MS, Al-Daghri N, Abdulkareem A, Draz HM, Yakout SM, Alnaami AM, Sabico S, Alenad AM, Chrousos GP.

BMC Cancer. 2013 Feb 4;13:54. doi: 10.1186/1471-2407-13-54.

16.

The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease.

Ades PA, Savage PD, Toth MJ, Schneider DJ, Audelin MC, Bunn JY, Ludlow M.

Int J Obes (Lond). 2008 Jun;32(6):967-74. doi: 10.1038/ijo.2008.6. Epub 2008 Feb 12.

PMID:
18268512
17.

Inflammatory markers and cardiovascular risk in the metabolic syndrome.

Espinola-Klein C, Gori T, Blankenberg S, Munzel T.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1663-74. Review.

PMID:
21196255
18.
19.

Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.

Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF.

Thromb Haemost. 2005 Dec;94(6):1190-5.

PMID:
16411393
20.

Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?

Mertens I, Van der Planken M, Corthouts B, Van Gaal LF.

Metabolism. 2006 May;55(5):650-5.

PMID:
16631442

Supplemental Content

Support Center